{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:32:47Z","timestamp":1789435967346,"version":"build-2803163510"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>This study aims to investigate the pathogenesis, clinical manifestations, and prognosis of interstitial lung disease (ILD) induced by cetuximab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>A single case of a colorectal cancer patient who underwent radical resection and descending colon-rectal anastomosis for sigmoid colon cancer on October 22, 2020, was selected. Postoperative pathology revealed moderately differentiated adenocarcinoma confined to the mucosa, measuring approximately 0.5\u00d70.2\u00d70.2 cm, with no cancer involvement in the proximal and distal resection margins, and metastatic carcinoma observed in 1 out of 5 pericolic lymph nodes. On July 29, 2021, due to a significant increase in CA19\u20139 levels, chest and abdominal CT scans, along with brain MRI, indicated enlarged retroperitoneal lymph nodes. The patient was afebrile and without respiratory symptoms such as cough, sputum production, chest tightness, or shortness of breath, and imaging suggested disease progression. With no significant abnormalities in C-reactive protein, blood routine, and no evidence of infection, cetuximab-related ILD was considered. Due to mild inflammation, the patient continued cetuximab combined with chemotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>This study suggests that cetuximab can induce ILD, and the onset time may be associated with factors such as serum albumin levels and underlying pulmonary diseases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The incidence of cetuximab-induced ILD is low and relatively rare, with non-specific clinical symptoms. Clinically, treatment plans should be tailored to the patient\u2019s actual condition to control disease progression and improve patient prognosis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1541649","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T04:10:29Z","timestamp":1753330229000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: A case of interstitial pneumonia in a colorectal cancer patient with a history of lung cancer treated with cetuximab"],"prefix":"10.3389","volume":"15","author":[{"given":"Yang","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoqun","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Qing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1186\/s43046-023-00160-9","article-title":"Impact of cetuximab plus cisplatin alone versus cetuximab plus cisplatin and paclitaxel regimen on humanistic outcomes in head and neck cancer","volume":"35","author":"Avinash","year":"2023","journal-title":"J Egyptian Natl Cancer Institute"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e36379","DOI":"10.1097\/MD.0000000000036379","article-title":"Case report: Interstitial lung disease of XELOEX chemotherapy with cetuximab in advanced colon cancer induced","volume":"102","author":"Shao","year":"2023","journal-title":"Medicine"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: A Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0791-0","article-title":"An update on the efficacy and safety of cetuximab in metastatic colorectal cancer: A narrative review","volume":"35","author":"Fornasier","year":"2018","journal-title":"Adv Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.7447","article-title":"Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy","volume":"26","author":"Vermorken","year":"2007","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyu128","article-title":"Incidence and clinical features of drug-induced lung injury in patients with advanced colorectal cancer receiving cetuximab: Results of a prospective multicenter registry","volume":"44","author":"Satoh","year":"2014","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/00016489.2017.1355566","article-title":"Mild pulmonary emphysema as a risk factor for interstitial lung disease associated with cetuximab treatment in squamous cell carcinoma of the head and neck","volume":"137","author":"Okamoto","year":"2017","journal-title":"Acta Otolaryngologica"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001104","article-title":"A case of severe pneumonia induced by cetuximab in the treatment of metastatic colorectal cancer: A literature review","volume":"26","author":"Yang","year":"2019","journal-title":"Chin J Oncol Biol Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2014.233","article-title":"Advances in the application of cetuximab in maintenance therapy following first-line treatment for metastatic colorectal cancer","volume":"41","author":"Song","year":"2021","journal-title":"Chin J Anorectal Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1006-4931.2021.09.021","article-title":"Observation of the efficacy of cetuximab combined with the FOLFOX4 regimen in treating postoperative recurrence of colorectal cancer","volume":"30","author":"Sun","year":"2021","journal-title":"China Pharm Industry"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1177\/10600280241284923","article-title":"Tolerability assessment of tyrosine kinase inhibitors in patients with solid tumor Malignancies and hypoalbuminemia","volume":"59","author":"Sadrameli","year":"2025","journal-title":"Ann Pharmacother"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2011.11.009","article-title":"Adverse pulmonary reactions associated with monoclonal antibody use in cancer patients","volume":"106","author":"Kang","year":"2012","journal-title":"Respir Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S488998","article-title":"Hypoalbuminemia is associated with higher 90-day mortality and poor prognosis in patients with esophageal squamous cell carcinoma and liver cirrhosis receiving radiotherapy-based therapy","volume":"16","author":"Hua","year":"2024","journal-title":"Cancer Manag Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/00016489.2017.1355566","article-title":"Mild pulmonary emphysema as a risk factor for interstitial lung disease associated with cetuximab treatment in patients with squamous cell carcinoma of the head and neck","volume":"137","author":"Okamoto","year":"2017","journal-title":"Acta Otolaryngologica"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1541649\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T04:10:34Z","timestamp":1753330234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1541649\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":14,"alternative-id":["10.3389\/fonc.2025.1541649"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1541649","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"article-number":"1541649"}}